Recent News

• 06.05.2025 - 2025 Jefferies Global Healthcare Conference
• 05.29.2025 - Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
• 05.07.2025 - Chip Clark
• 05.06.2025 - Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
• 05.05.2025 - Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
• 05.05.2025 - Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
• 04.17.2025 - Aldeyra Therapeutics Appoints Chip Clark to Board of Directors
• 04.03.2025 - Aldeyra Conference Call to Discuss Regulatory Update on Reproxalap in Dry Eye Disease

Recent Filings

• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - 8-K Current report
• 05.06.2025 - EX-99.1 EX-99.1
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.18.2025 - 3 Initial statement of beneficial ownership of securities
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.17.2025 - 8-K Current report
• 04.17.2025 - EX-99.1 EX-99.1